GI-102 for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 Apr 2023: Trial registered, NCT05824975
  2. 30 May 2023: Trial started, NCT05824975

The trials

NCT05824975: A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

State
Under way
Phase
Phase 1 and Phase 2
People
358 planned
Started
30 May 2023
Primary completion
12 Nov 2025
Arms
GI-102
Results
None posted
  1. 24 Apr 2023: Trial registered
  2. 30 May 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.